First human test for new gut infection drug shows early safety profile
NCT ID NCT06639997
Summary
This early-stage study tested a single dose of an experimental drug called AZD5148, which is being developed to treat Clostridioides difficile (C. diff) infections. The main goal was to check if the drug was safe and to see how the body processes it in 16 healthy Japanese adults. Researchers gave the drug as either an injection into a vein or a muscle and closely monitored participants for side effects for over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIOIDES DIFFICILE INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Sumida-ku, 130-0004, Japan
Conditions
Explore the condition pages connected to this study.